1209465-70-2

Basic information

• Product Name: C₂₀H₁₉N₇O₅
• Synonyms: C₂₀H₁₉N₇O₅
• CAS NO: 1209465-70-2
• Molecular Weight: 437.415
• Mol File: 1209465-70-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₂₀H₁₉N₇O₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₀H₁₉N₇O₅(1209465-70-2)
• EPA Substance Registry System: C₂₀H₁₉N₇O₅(1209465-70-2)

Safety Data

• Hazardous Substances Data: 1209465-70-2(Hazardous Substances Data)

Upstream product

• 155405-79-1 4-(3-bromo-4-oxobutyl)benzoic acid methyl ester 
• 1898-72-2 2,6-dimethoxy-1,3,5-triazine 
• 137281-39-1 4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl )ethyl]benzoic acid 
• 3140-73-6 2-chloro-4,6-dimethoxy-1 ,3,5-triazine 

Downstream Products

• 204257-42-1 (S)-4-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)-5-(benzyloxy)-5-oxopentanoic acid 
• 1209465-72-4 C₂₄H₂₄N₆O₈ 
• 165049-28-5 N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid diethyl ester 4-methylbenzenesulfonic acid salt 
• 146943-43-3 N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid diethyl ester 

Relevant articles and documents

Synthesis and physicochemical characterization of the impurities of pemetrexed disodium, an anticancer drug

A physicochemical characterization of the process-related impurities associated with the synthesis of pemetrexed disodium was performed. The possibility of pemetrexed impurities forming has been mentioned in literature, but no study on their structure has been published yet. This paper describes the development of the synthesis methods for these compounds and discusses their structure elucidation on the basis of two-dimensional NMR experiments and MS data. The identification of these impurities should be useful for the quality control during the production of the pemetrexed disodium salt.

BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compoun